Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (2979)	5/28/1998 6:47:00 PM
From: Kenneth R Miller	Read Replies (2) \| Respond to of 9523

Has the thread read this one yet? NEW YORK, May 28 (Reuters) - With a drug potentially better than Viagra in clinical trials, the next biotechnology stock to watch might be that of ICOS Corp., according to the June 8 issue of Business Week. Jim McCamant, editor of Medical Technology Stock newsletter, told Business Week ICOS' anti-impotence pill, "will be a potentially better product than Pfizer's PFE.N Viagra because it has fewer side effects." The drug, called IC351, but still without a brand name, is in Phase II trials on men with erectile dysfunction. McCamant told Business Week he expects tests will validate the drug's safety before the year-end and trials next year will evaluate its efficacy. But ICOS has yet to generate the same excitement among investors. It's stock closed at 16-1/4, down from a December 30 peak of 18-7/8, the magazine said.